Bergen Brunswig-Ivax Deal Clears Hurdle

Bergen Brunswig Corp.’s proposed acquisition of Miami-based generic drug-maker Ivax Corp. has cleared the waiting period set by the Federal Trade Commission, the companies said Thursday. The deal, which has raised eyebrows among investors and analysts, still must be approved by shareholders. Some analysts have speculated that the Orange-based pharmaceutical distributor’s $1.4-billion purchase of Ivax will be restructured or even collapse in the wake of investor dissatisfaction over the original terms. But both companies have insisted that the deal is still on.